BELLEVUE, Wash.--(BUSINESS WIRE)--Calcionics Corporation, an emerging biotechnology company developing novel therapies to prevent and treat cardiovascular disease by targeting vascular calcification, or “hardening of the arteries,” today announced the appointment of Daniel O. Wilds as Executive Chairman of the Company’s Board of Directors. Mr. Wilds is a senior healthcare executive with extensive private and public company leadership and board experience.
